Jaguar Health FY2025 net loss widens to $53.6M; enters Future Pak deal for non-dilutive capital; Nasdaq appeal pending

Jaguar Health, Inc.

Net revenue FY2025 $11.5M (-1.5% YoY); Q4 2025 net revenue $3.2M (+5% QoQ, -8% YoY).
Net loss attributable to common stockholders FY2025 $53.6M vs $38.5M; loss from operations $45.9M.
Mytesi prescription volume down 3.7% in 2025 vs 2024; Q4 2025 down 12.2% YoY.
Entered license agreement with Future Pak Jan 2026: $16M up-front non-dilutive capital, $2M additional upon conditions; FP to commercialize Mytesi and Canalevia-CA1.
Received Nasdaq noncompliance notice; appeal hearing April 7, 2026; delisting stayed pending decision.

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Jaguar Health, Inc. reported year ended December 31, 2025 results: revenue $11.5 million, net income $53.6 million net loss, EPS ($24.27) per share.

Period: year ended December 31, 2025
Revenue: $11.5 million
Net income: $53.6 million net loss
EPS: ($24.27) per share
Result: reported results

Exact text from the filing

the total net revenue in the fourth quarter of 2024, which totaled approximately $3.5 million. • In 2025, approximately $11.2 million out of the Company’s total net revenue of $11.5 million was generated by sales of Mytesi and Canalevia-CA1. Under the terms of the license agreement Jaguar entered with Future Pak (“FP”) in January 2026, FP will be responsible for all

View on SEC.gov

Browse all earnings releases →

Jaguar Health, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-26-144604

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.